The European Medicines Agency has determined that Remsima, a biosimilar, is comparable to the reference product Remicade® in terms of safety, efficacy and quality across all approved indications The ...

18 th March 2016, Amsterdam, Netherlands. Real-world studies with nearly 600 inflammatory bowel disease (IBD) patients in eight countries show comparable efficacy and safety following a switch to ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Healthcare today announced that the European Commission has approved Remsima SC ™ (CT-P13 SC, biosimilar infliximab) for patients with RA. 1 Remsima SC ...

Celltrion Healthcare has today announced the launch of Remsima™ (infliximab) in 12 European markets: Austria, Belgium, Denmark, France, Germany, Greece, Italy ...

Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for ...

INCHEON, South Korea--(BUSINESS WIRE)--Today, Celltrion Healthcare announced two new data sets on the SC formulation of infliximab, Remsima ® (CT-P13) in IBD, at the European Crohn’s and Colitis ...

Please provide your email address to receive an email when new articles are posted on . The European Commission has extended approval for Celltrion Healthcare’s subcutaneous infliximab biosimilar to ...

TORONTO, Feb. 1, 2021 /CNW Telbec/ - Celltrion Healthcare Canada Limited announced today that Health Canada has granted a notice of compliance (NOC) for Remsima™ SC (CT-P13 SC) in Canada for the ...

Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV ...